Evidence map›Paper›PMID 41551417›Full record

ArticleOral oncology reports2024

Oral manifestation associated with avelumab.

Kevin Chung, Annu Singh, Joseph M Huryn, Cherry L Estilo

Abstract read
In one paragraph

Article in Oral oncology reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Kevin ChungDental Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA.
Annu SinghDental Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 1006, USA.
Joseph M HurynDental Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA.
Cherry L EstiloDental Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Emerging immunotherapies are becoming more prominent in treating various cancers. However, side effects and toxicities can induce systemic and oral manifestations which can be debilitating and negatively affect a patient's quality of life. Avelumab is a relatively recent immunotherapy drug that is used in the treatment of both renal and metastatic urothelial carcinomas. However, oral manifestation, to the best of our knowledge, has not been reported in the literature in association. The purpose of this case report is to describe an oral manifestation associated with avelumab, and subsequent management to obtain resolution of symptoms.

Indexed as

AvelumabImmune checkpoint inhibitorsMucositisOral adverse events

Identifiers

PMID41551417
PMCPMC12807550

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.